A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING)
A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)
-
Clinical Trial Information
Trial Contact: Donaldson, Karin M; Frankos, Marie; Djuro, Victor; Caldwell, Chloe M; Ribacchi, Stephanie
Trial Phone: 321.841.9821 ; 321.841.7303 ; 321.841.7477 ; (321)841.1107 ; 321-841-1077
-
IRB No: 22.222.10
Protocol Abbrev: TBio-4101-001
Principal Investigator: Sajeve Samuel Thomas, MD
Phase: Drug: Phase I
Age Group: Adult
Secondary Protocol No: TBio-4101-001
Treatment: Biological: TBio-4101 TBio-4101 is an autologous selected and expanded tumor infiltrating lymphocyte (TIL) product generated following ex vivo expansion of tumor reactive TIL population found in tumor harvest. After preparation with non-myeloablative lymphodepletion chemotherapy (cyclophosphamide and fludarabine) followed by TBio-4101 and IL-2. Other Name: TIL, autologous, tumor-reactive, T-cell product Drug: Pembrolizumab Pembrolizumab will be administered after TIL infusion and continue every 3 weeks for up to 2 years. Other Name: Keytruda
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT05576077
-
Objective
This is a Phase 1 study to investigate TBio-4101. TBio-4101 is an autologous tumor infiltrating lymphocyte (TIL) therapy that utilizes tumor specific antigens to select, sort, and expand patient-specific tumor-reactive T-cells to be reinfused into the patient. The adoptive cell therapy is further enhanced through the use of non-myeloablative chemotherapy prior to TIL infusion, followed by the TIL plus IL-2 infusion. Pembrolizumab is provided after the resolution of IL-2 toxicities. The trial is open to solid tumors of varying tumor mutational burdens.
-
Key Eligibility
Key Inclusion Criteria:
*Advanced or metastatic breast carcinoma, colorectal adenocarcinoma, or uveal melanoma that has failed or is refractory to standard of care therapy
*Have at least one target lesion that can be used for response assessments and have at least 1 tumor amenable for tissue harvest for TIL manufacturing.
*ECOG performance status of 0 or 1
*Demonstrate adequate organ function
*Additional inclusion criteria exist
